TRANSGENE BIOTEK LTD.
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
TRANSGENE BIOTEK LTD. had its IPO on under the ticker symbol TRABI.
The company operates in the sector and industry. TRANSGENE BIOTEK LTD. has a staff strength of 0 employees.
Shares of TRANSGENE BIOTEK LTD. opened at 4.19 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of 3.9 - 4.19, and closed at 3.97.
This is a -0.75% slip from the previous day's closing price.
A total volume of 86,174 shares were traded at the close of the day’s session.
In the last one week, shares of TRANSGENE BIOTEK LTD. have increased by +6.15%.
TRANSGENE BIOTEK LTD.'s Key Ratios
TRANSGENE BIOTEK LTD. has a market cap of 0, indicating a price to book ratio of and a price to sales ratio of .
In the last 12-months TRANSGENE BIOTEK LTD.’s revenue was 0 with a gross profit of 0 and an EBITDA of 0. The EBITDA ratio measures TRANSGENE BIOTEK LTD.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, TRANSGENE BIOTEK LTD.’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q0.33333333333333, TRANSGENE BIOTEK LTD.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
TRANSGENE BIOTEK LTD.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at per share while it has a forward price to earnings multiple of and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TRANSGENE BIOTEK LTD.’s profitability.
TRANSGENE BIOTEK LTD. stock is trading at a EV to sales ratio of and a EV to EBITDA ratio of . Its price to sales ratio in the trailing 12-months stood at .
TRANSGENE BIOTEK LTD. stock pays annual dividends of per share, indicating a yield of and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
TRANSGENE BIOTEK LTD. ended 1970 with 0 in total assets and 0 in total liabilities. Its intangible assets were valued at 0 while shareholder equity stood at 0.
TRANSGENE BIOTEK LTD. ended 1970 with 0 in deferred long-term liabilities, 0 in other current liabilities, in common stock, 0 in retained earnings and 0 in goodwill. Its cash balance stood at 0 and cash and short-term investments were 0. The company’s total short-term debt was 0 while long-term debt stood at 0.
TRANSGENE BIOTEK LTD.’s total current assets stands at 0 while long-term investments were 0 and short-term investments were 0. Its net receivables were 0 compared to accounts payable of 0 and inventory worth 0.
In 1970, TRANSGENE BIOTEK LTD.'s operating cash flow was 0 while its capital expenditure stood at 0.
Comparatively, TRANSGENE BIOTEK LTD. paid 0 in dividends in 1970.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
TRANSGENE BIOTEK LTD. stock is currently trading at 3.97 per share. It touched a 52-week high of and a 52-week low of . Analysts tracking the stock have a 12-month average target price of .
Its 50-day moving average was 2.84 and 200-day moving average was 2.95 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About TRANSGENE BIOTEK LTD.